All news

ResMed quarterly update to test full-year guidance

Alpha Vantage · Kalkine Media · · AI-summarised by FinFlash

ResMed (ASX:RMD) reports quarterly results this week, giving the market its first look at performance against full-year guidance. Analysts will focus on gross margin trends, the Astral ventilator sales suspension, software divestment progress, and how new weight-loss medicines affect sleep apnoea demand. Capital management and pipeline updates are also in view.

Read original source

RMD company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.